Clinical Review

ABC of clinical haematology: The acute leukaemias

BMJ 1997; 314 doi: https://doi.org/10.1136/bmj.314.7082.733 (Published 08 March 1997) Cite this as: BMJ 1997;314:733
  1. R J Liesner,
  2. A H Goldstone

    Acute leukaemia is a clonal (that is, derived from a single cell) malignant disorder affecting all age groups from infancy to old age. It is characterised by the accumulation of abnormal white blood cells in the bone marrow which replace normal marrow tissue, including haemopoietic precursor cells. This results in bone marrow failure and peripheral blood involvement. Infiltration of various organs is also a feature of some forms of leukaemia.

    Aetiological factors in acute leukaemia

    • Unknown (usually)

    • Hereditary

    • Down's syndrome

    • Bloom's syndrome

    • Fanconi's anaemia

    • Ataxia telangiectasia

    • Kleinfelter's syndrome

    • Osteogenesis imperfecta

    • Wiskott-Aldrich syndrome

    • Leukaemia in siblings

    • Chemicals

    • Chronic benzene exposure

    • Alkylating agents (chlorambucil, melphalan)

    • Radiation

    • Predisposing haematological diseases (myeloproliferative disorders, myelodysplasia, and aplastic anaemia).

    • Viruses (HTLV-I causing adult T cell leukaemia/lymphoma)

    In most cases the aetiology is not obvious, but some constitutional and acquired disorders do predispose to acute leukaemia.

    In the past 40 years advances in the treatment of acute leukaemia have improved the chance of cure from virtually zero to 20-75%, depending on age and type of leukaemia. This has largely been the result of clinical trials—many of which are still ongoing—and the development and continued improvements in bone marrow transplantation.

    Classification

    Acute leukaemia is subdivided into (a) acute lymphoblastic leukaemia, in which the abnormal proliferation is in the lymphoid progenitor cells (that is, immature lymphocytes) and (b) acute myeloid leukaemia, which involves the myeloid lineages (that is, cells from which neutrophils, eosinophils, monocytes, basophils, megakaryocytes, etc are derived). The distinction between the two leukaemias is based on morphological, cytochemical, and immunological differences and is of paramount importance as the treatment and prognosis are usually different.

    FAB* classification of acute myeloid leukaemia

    M0 Acute myeloid leukaemia with minimal evidence of myeloid differentiation

    M1 Acute myeloblastic leukaemia without maturation

    M2 Acute myeloblastic leukaemia with maturation

    M3 Acute promyelocytic leukaemia

    M4 Acute myelomonocytic leukaemia

    M5 Acute …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe